APA (7th ed.) Citation

Xu, W., Yang, H., Xu, K., Zhu, A., Hall, S. R. R., Jia, Y., . . . Yao, F. (2025). Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma. Clinical & Translational Medicine, 15(4), 1. https://doi.org/10.1002/ctm2.70281

Chicago Style (17th ed.) Citation

Xu, Weijiao, et al. "Transitional CXCL14+ Cancer‐associated Fibroblasts Enhance Tumour Metastasis and Confer Resistance to EGFR‐TKIs, Revealing Therapeutic Vulnerability to Filgotinib in Lung Adenocarcinoma." Clinical & Translational Medicine 15, no. 4 (2025): 1. https://doi.org/10.1002/ctm2.70281.

MLA (9th ed.) Citation

Xu, Weijiao, et al. "Transitional CXCL14+ Cancer‐associated Fibroblasts Enhance Tumour Metastasis and Confer Resistance to EGFR‐TKIs, Revealing Therapeutic Vulnerability to Filgotinib in Lung Adenocarcinoma." Clinical & Translational Medicine, vol. 15, no. 4, 2025, p. 1, https://doi.org/10.1002/ctm2.70281.